Are you already a client or interested in our services? We are happy to help you.
We are happy to speak to you in person. Call us or click on the link below for more contact options and locations.
The Netherlands
0800 17 37
Belgium
+32 (0)32 86 69 80
Switzerland
+41 (0)43 377 11 11
We are happy to speak to you in person. Call us or click on the link below for more contact options and locations.
The Netherlands
+31 (0)20 348 87 00
United Kingdom
+44 (0)20 36 36 94 00
France
+33 (0)18 375 62 73
We are happy to speak to you in person. Call us or click on the link below for more contact options and locations.
The Netherlands
+31 (0)20 348 80 00
United States of America
+1 (0)21 237 601 34
Immunovia
Joint Global Coordinator and Joint Bookrunner
Kempen & Co acted as Joint Global Coordinator and Joint Bookrunner in Immunovia’s capital increase via accelerated bookbuild offering of c. SEK 400 million
Transaction highlights
- Placement of 2,948,228 shares, c. 15% of Immunovia’s outstanding share capital, at a price of SEK 135 per share, representing a discount of c. 10% to the 30-day VWAP
- Gross proceeds amount to c. SEK 400 million, representing the largest capital increase since the Company’s IPO in 2015
- The proceeds are expected to be used to fund the Company’s investments in an accelerated commercialization start for IMMray™ PanCan-d and for general corporate purposes
- In addition to strong support from existing and new local investors, the Company also attracted sizeable demand from international investors thus further broadening its shareholder base
- Kempen & Co assisted the Company with extensive investor engagement over the last twelve months, across its network spanning both Europe and the United States
- Over the past 18 months, this transaction marks Kempen & Co’s fifth in the Nordics region, the very first in which it acted as a Global Coordinator, where it retains a strong ambition to work with innovative companies
Company description
Immunovia AB is a diagnostic company that is developing and commercializing highly accurate blood tests for the early detection of cancer and autoimmune diseases based on Immunovia's proprietary test platform called IMMray™. Tests are based on antibody biomarker microarray analysis using advanced machine-learning and bioinformatics to single-out a set of relevant biomarkers that indicate a certain disease. Thus, forming a unique “disease biomarker signature". The company was founded in 2007, based on cancer studies and ground-breaking research in the Department of Immuntechnology at Lund University and CREATE Health Cancer Center, Sweden. The first product, IMMray™ PanCan-d, is undergoing clinical evaluation in some of the world's largest clinical studies for pancreatic cancer, PanFAM-1, PanSYM-1 and PanDIA-1 and is currently entering the final validation for sales start Q4 2020. When validated, IMMray™ PanCan-d will be the first blood-based test for early diagnosis of pancreatic cancer on the market, with a potential to significantly improve patient survival and outcome. Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm.